Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales. Is the Stock Still a Buy After Skyrocketing More Than 5X?
Key PointsIt's a cancer medication with immense potential.
Trading
Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales. Is the Stock Still a Buy After Skyrocketing More Than 5X?
Cross-asset desk, Private Trade News (2026-08-28): Key PointsIt's a cancer medication with immense potential. Primary source: original at Nasdaq Market Structure (nasdaq.com).